Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030, covering various important aspects of the industry and identifying key future growth opportunities.

The Biopharmaceutical Contract Manufacturing Market is projected to grow at an annualized rate of ~8%, till 2030

The Antibody Contract Manufacturing Market is projected to grow at an annualized rate of 12%, till 2030

Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions

Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers

Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages

The benefits of engaging a CMO or CDMO for antibody development and production extend beyond fulfilling the needs of small companies; access to new technologies and operational flexibility are attractive attributes to larger players as well

The “Targeted Protein Degradation Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics and affiliated technologies, over the next decade.

More than 80 companies presently claim to have the required expertise to design and manufacture different types of labels, using both conventional and advanced printing methods, for use in medical devices, claims Roots Analysis

The “Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers” ...

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts

More than 100 subcutaneous biologics have been approved and over 350 such drug candidates are being evaluated in the clinical stages of development, for the treatment of a wide variety of disease indications, claims Roots Analysis

The Medical Device Label Contract Manufacturing market is projected to grow at an annualized rate of ~9.8%, till 2030

Nearly 300 non-invasive diagnostic tests, designed for the detection of various types of cancers, are either already available in the market or under development across the world

The “Cell and Advanced Therapies Supply Chain Management Market, 2020-2030” report features an extensive study of the innovative software solutions that are being used...

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts

The Subcutaneous Biologic Drugs And Affiliated Technologies Market is projected to be worth over USD 180 billion by 2030

The Medical Device Label Contract Manufacturing Market is projected to grow at an annualized rate of ~9.8%, till 2030

The non-invasive cancer diagnostics market is projected to grow at an annualized rate of ~20%, till 2030

Presently, over 160 innovative, software enabled systems are being used to efficiently manage and streamline various aspects of the complex supply chain of cell and advanced therapies

Outsourcing the manufacturing of labels is a popular trend among medical device developers, enabling such companies to leverage the advanced capabilities of CMOs, while focusing on the core aspects of product development

The Targeted Protein Degradation Market is projected to grow at an annualized rate of more than 30% till 2030

Subcutaneous drug delivery, given the use of tailored formulation development solutions, has brought about a paradigm shift in at-home healthcare, enabling users to administer (life-saving) medications without having to rely on medical professionals

Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access

Given the cost saving potential across different processes and operations, the cell and advanced therapies supply chain management market is projected to grow at an annualized rate of ~25% rapid till 2030